{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "exchange": "HKG", "shortName": "INNOCARE-B", "longName": "InnoCare Pharma Limited", "messageBoardId": "finmb_643357876", "exchangeTimezoneName": "Asia/Hong_Kong", "exchangeTimezoneShortName": "HKT", "gmtOffSetMilliseconds": 28800000, "market": "hk_market", "esgPopulated": false, "regularMarketChangePercent": -3.164549, "regularMarketPrice": 9.18, "marketState": "CLOSED", "fiftyTwoWeekHighChangePercent": -0.4226415, "fiftyTwoWeekLow": 7.2, "fiftyTwoWeekHigh": 15.9, "earningsTimestamp": 1648033140, "earningsTimestampStart": 1648033140, "earningsTimestampEnd": 1648033140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.72, "epsForward": -0.28, "epsCurrentYear": -0.42, "priceEpsCurrentYear": -21.857143, "sharesOutstanding": 1764320000, "bookValue": 4.531, "fiftyDayAverage": 8.9256, "fiftyDayAverageChange": 0.25440025, "fiftyDayAverageChangePercent": 0.028502313, "twoHundredDayAverage": 10.8186, "twoHundredDayAverageChange": -1.6385994, "twoHundredDayAverageChangePercent": -0.15146132, "marketCap": 16196458496, "forwardPE": -32.785717, "priceToBook": 2.026043, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "priceHint": 3, "regularMarketChange": -0.29999924, "regularMarketTime": 1683878916, "regularMarketDayHigh": 9.6, "regularMarketDayRange": "9.07 - 9.6", "regularMarketDayLow": 9.07, "regularMarketVolume": 3849000, "regularMarketPreviousClose": 9.48, "bid": 9.18, "ask": 9.22, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 9.27, "averageDailyVolume3Month": 5532668, "averageDailyVolume10Day": 2594400, "fiftyTwoWeekLowChange": 1.9800005, "fiftyTwoWeekLowChangePercent": 0.27500007, "fiftyTwoWeekRange": "7.2 - 15.9", "fiftyTwoWeekHighChange": -6.7199993, "firstTradeDateMilliseconds": 1584927000000, "symbol": "9969.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building 8", "address2": "No. 8 Life Science Park Road Zhongguancun Life Science Park Changping District", "city": "Beijing", "zip": "102206", "country": "China", "phone": "86 10 6660 9999", "fax": "86 10 6070 2992", "website": "https://www.innocarepharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jisong  Cui Ph.D.", "age": 59, "title": "Co-Founder, Exec. Chairperson & CEO", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 1078307, "fmt": "1.08M", "longFmt": "1,078,307"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Renbin  Zhao Ph.D.", "age": 53, "title": "VP of Regulatory Affairs & Clinical Devel. and Exec. Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 418533, "fmt": "418.53k", "longFmt": "418,533"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Nan  Gao", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Xiangyang  Chen Ph.D.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Junsu  Wang", "age": 46, "title": "Gen. Counsel", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Xiaodong  Jin", "age": 49, "title": "Chief Commercial Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Xiang-Yang  Zhang", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Davy  Ouyang Ph.D.", "title": "VP & Head of Biology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Pui Shan  Lee", "title": "Company Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James  Deng", "title": "Member of Scientific Advisory Board in Sales and Marketing", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}